Alto Neuroscience (ANRO) Non-Current Assets (2023 - 2026)
Alto Neuroscience (ANRO) posted Non-Current Assets of $7.1 million for Q1 2026, up 2.32% sequentially from $7.0 million in Q4 2025, and down 15.0% YoY from $8.4 million in Q1 2025.
Alto Neuroscience (ANRO) Non-Current Assets (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Non-Current Assets for 4 years, with the latest figure at $7.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 15.0% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 million (up 11.52% YoY) and the FY2025 annual result came in at $7.0 million, down 15.04% from the prior year.
- Non-Current Assets rose to $7.1 million in Q1 2026 per ANRO's latest filing, from $7.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $8.4 million in Q1 2025 and troughed at $1.2 million in Q4 2023.
- A 4-year average of $5.9 million and a median of $7.3 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets jumped 563.3% in 2024, then slipped 15.04% in 2025.
- Over 4 years, Non-Current Assets stood at $1.2 million in 2023, then surged by 563.3% to $8.2 million in 2024, then retreated by 15.04% to $7.0 million in 2025, then climbed by 2.32% to $7.1 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $7.1 million, $7.0 million, and $7.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | 6.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.75 Mn |
| Mar 31, 2026 | 7.13 Mn |
| Dec 31, 2025 | 6.97 Mn |
| Sep 30, 2025 | 7.56 Mn |
| Jun 30, 2025 | 8.03 Mn |
| Mar 31, 2025 | 8.39 Mn |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | 8.08 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 1.24 Mn |